Patent US6037331A successfully refreshed from Google Patents.
US6037331A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions for prevention of inflammation and adhesion formation uses thereof
Assignee: Poly Med Inc
•
Filing: 1998-11-12
•
Granted: 2000-03-14
•
Expires: 2018-11-12
Abstract
Abstract Pharmaceutical compositions comprising hyaluronic acid, non-steroidal inflammatory drugs, and at least one organic salt of at least one divalent metal, and methods of using these compositions for the inhibition of inflammation and adhesion formation are described. Preferred organic salts of divalent metals include magnesium acetate, zinc acetate, calcium gluconate, and ferrous gluconate. A preferred non-steroidal anti-inflammatory drug is cyclosporin A.
Inventors
- 👤 Shalaby W. Shalaby
- 👤 Julie Miller Hasenwinkel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 19:15
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/185; A61K31/19; A61K31/33; A61K31/395; A61K31/40; A61K31/726; A61K31/728; A61K33/00; A61K33/06; A61K33/24; A61K33/26; A61K33/30; A61K45/00; A61K45/06; C; C08; C08G; C08G18/00; C08G18/06; C08G18/08; C08G18/14; C08G18/28; C08G18/40; C08G18/63; C08G18/632; C08G2110/00; C08G2110/0008; C08G2110/0041; C08G2110/005; C08G2110/0083
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
51 words
A therapeutic composition for use in inhibiting tissue inflammation and adhesion formation in a mammal, said composition comprising hyaluronic acid, a non-steroidal anti-inflammatory agent, and at least one organic salt of at least one divalent metal selected from the group consisting of magnesium actate, zinc acetate, calcium gluconate and ferrous gluconate.
Claim 2
Dependent Claim
51 words
A therapeutic composition for use in inhibiting tissue inflammation and adhesion formation in a mammal, said composition comprising hyaluronic acid, a non-steroidal anti-inflammatory agent, and at least one organic salt of at least one divalent metal selected from the group consisting of magnesium actate, zinc acetate, calcium gluconate and ferrous gluconate.
Claim 3
Dependent Claim
19 words
The therapeutic composition of claim 1 wherein the molecular weight of the HA is at least 1.0×10 6 Daltons.
Claim 4
Dependent Claim
23 words
The therapeutic composition of claim 1 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of tolmetin, ibuprofen, naproxen and peptides.
Claim 5
Dependent Claim
14 words
The therapeutic composition of claim 1 wherein the non-steroidal anti-inflammatory agent is a peptide.
Claim 6
Dependent Claim
12 words
The therapeutic composition of claim 4 wherein the peptide is cyclosporin A.
Claim 7
Dependent Claim
17 words
The therapeutic composition of claim 1 wherein the organic salt of a divalent metal is magnesium acetate.
Claim 8
Dependent Claim
17 words
The therapeutic composition of claim 1 wherein the organic salt of a divalant metal is zinc acetate.
Claim 9
Dependent Claim
17 words
The therapeutic composition of claim 1 wherein the organic salt of a divalant metal is calcium gluconate.
Claim 10
Dependent Claim
17 words
The therapeutic composition of claim 1 wherein the organic salt of a divalant metal is ferrous gluconate.
Claim 11
Dependent Claim
17 words
The therapeutic composition of claim 1 wherein the viscosity of the composition is less than 18 dl/g.
Claim 12
Dependent Claim
49 words
A therapeutic composition for use in inhibiting tissue inflammation and adhesion formation in a mammal, said composition comprising hyaluronic acid, cyclosporin A and at least one organic salt of at least one divalent metal selected from the group consisting of magnesium acetate, zinc acetate, calcium gluconate and ferrous gluconate.
Claim 13
Dependent Claim
49 words
A therapeutic composition for use in inhibiting tissue inflammation and adhesion formation in a mammal, said composition comprising hyaluronic acid, cyclosporin A and at least one organic salt of at least one divalent metal selected from the group consisting of magnesium acetate, zinc acetate, calcium gluconate and ferrous gluconate.
Claim 14
Dependent Claim
17 words
The therapeutic composition of claim 11 wherein the organic salt of a divalent metal is ferrous gluconate.
Claim 15
Independent Claim
80 words
A method of inhibiting or mediating tissue inflammation in mammal tissue, said method comprising administering to said mammal a therapeutic composition comprising hyaluronic acid, a non-steroidal anti-inflammatory agent, and at least one organic salt of at least one divalent metal in a dosage effective to inhibit or mediate local inflammation and adhesion formation in said tissue, wherein said organic salt of a divalent metal is selected from the group consisting of magnesium acetate, zinc acetate, calcium gluconate and ferrous gluconate.
Claim 16
Independent Claim
80 words
A method of inhibiting or mediating tissue inflammation in mammal tissue, said method comprising administering to said mammal a therapeutic composition comprising hyaluronic acid, a non-steroidal anti-inflammatory agent, and at least one organic salt of at least one divalent metal in a dosage effective to inhibit or mediate local inflammation and adhesion formation in said tissue, wherein said organic salt of a divalent metal is selected from the group consisting of magnesium acetate, zinc acetate, calcium gluconate and ferrous gluconate.
Claim 17
Dependent Claim
21 words
The method of claim 13 wherein said mammal is at risk of tissue adhesion formation as a result of tissue injury.
Claim 18
Dependent Claim
25 words
The method of claim 13 wherein said mammal is at risk of tissue adhesion formation which is pathological in origin or the result of surgery.
Claim 19
Dependent Claim
15 words
The method of claim 15 wherein said surgery occurs at the site of a tendon.
Claim 20
Dependent Claim
10 words
The method of claim 13 wherein said administration is local.
Claim 21
Dependent Claim
23 words
The method of claim 17 wherein the local administration is intraocular or at the site of the synovial fluid at an articulating joint.
Claim 22
Dependent Claim
13 words
The method of claim 18 wherein the non-steroidal anti-inflammatory agent is a peptide.
Claim 23
Dependent Claim
11 words
The method of claim 19 wherein the peptide is cyclosporin A.
References Cited (Backward Citations)
US5866554A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-03-14 | 2003-09-13 | 2004-03-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-03-14 | 2007-09-13 | 2008-03-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-03-14 | 2011-09-13 | 2012-03-14 | $7700.00 | Window Closed / Lapsed |